Nektar Therapeutics
NKTRNektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Drugs in Pipeline
14
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
NKTR-102
Tumor
NKTR-181 BID tablets
Low Back Pain
Treatment of Physician's Choice (TPC)
Locally Recurrent Breast Cancer
Eribulin
Metastasis
NKTR-102 q14d
Tumor
NKTR-181
Osteoarthritis of the Knee
NKTR-102 100 mg/m2
Tumor
NKTR-102 145 mg/m2
Malignant Solid Tumor
NKTR-255
Head and Neck Squamous Cell Carcinoma
irinotecan
Colorectal Cancer
NKTR-214
Unspecified Adult Solid Tumor, Protocol Specific
Bempegaldesleukin
Urinary Bladder Neoplasm
Rezpegaldesleukin
Moderate to Severe Atopic Dermatitis
LY3471851
Systemic Lupus Erythematosus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NKTR-102 | Phase 3 | Tumor | - | - |
NKTR-181 BID tablets | Phase 3 | Low Back Pain | - | - |
Treatment of Physician's Choice (TPC) | Phase 3 | Locally Recurrent Breast Cancer | - | - |
Eribulin | Phase 3 | Metastasis | - | - |
NKTR-102 q14d | Phase 2 | Tumor | - | - |
NKTR-181 | Phase 2 | Osteoarthritis of the Knee | - | - |
NKTR-102 100 mg/m2 | Phase 2 | Tumor | - | - |
NKTR-102 145 mg/m2 | Phase 2 | Malignant Solid Tumor | - | - |
NKTR-255 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
irinotecan | Phase 2 | Colorectal Cancer | - | - |
NKTR-214 | Phase 2 | Unspecified Adult Solid Tumor, Protocol Specific | - | - |
Bempegaldesleukin | Phase 2 | Urinary Bladder Neoplasm | - | - |
Rezpegaldesleukin | Phase 2 | Moderate to Severe Atopic Dermatitis | - | - |
LY3471851 | Phase 2 | Systemic Lupus Erythematosus | - | - |